Mutations in Presenilin1 and Presenilin2, the active centers of γ-secretase, and in APP itself have been identified in early-onset AD [15,27], many of which increase the amount of total Aβ [16] or the ratio of Aβ42/Aβ40 [28,29,30]. This evidence concerns the gene APP and Alzheimer disease.